On February 7th, at the beginning of the new year, EMICRO Biomedicine brought exciting news. In the Phase I clinical trial of its BTK inhibitor lymphoma project, for the second patient (with refractory and relapsed follicular lymphoma), after two months of administration at a 100 - mg dose, the tumor efficacy assessment showed not only good safety and tolerability, but also that the patient's lymphoma lesion was reduced by 82.91%.

The Year of the Snake brings spring early, and good news arrives during the festive season. On January 22, 2025, the BTK inhibitor jointly declared by EMICRO Biomedicine and Henan Normal University for the treatment of "multiple sclerosis (MS)" was approved by the National Medical Products Administration (NMPA) for a Phase I clinical trial.

On October 20th, the pharmaceutical and health conference of the 10th anniversary series of activities of Zhongyuan Bank, with the theme of "Technology driven Finance Empowering a Healthy Future", was successfully held in Zhengzhou. At the invitation of the conference, Dr. Yang Yinke, Chief Medical Officer of EMICRO Biomedicine Company, gave a special roadshow on "Innovative Drugs: Clinical Development of Next Generation BTK Inhibitors"; Li Peng, academician of the CAS Member and president of Zhengzhou University, made a keynote speech around the "Thinking about the future development of China's bio pharmaceutical industry"; Jiang Jiandong, academician of the CAE Member and president of the Institute of Materia Medica of the Chinese Academy of Medical Sciences, made a keynote speech around the Shining Chinese Original Drugs.

On the morning of September 24, 2024, Henan EMICRO Biomedicine Co., Ltd. achieved an important milestone - the Phase I clinical trial of the innovative anti-tumor drug TM471-1 capsule was launched.

On August 30, 2024, Wang Ningli, an expert in ophthalmology and otolaryngology, academician of the International Academy of Ophthalmology, and president of the Henan Academy of Medical Sciences, led a team of experts to Henan Zhimei Pharmaceutical Co., Ltd. for work research and was warmly welcomed by the company's leaders and employees.